{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T08:03:07Z","timestamp":1725091387819},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1038\/bjc.2011.306","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T20:06:57Z","timestamp":1312920417000},"page":"687-693","source":"Crossref","is-referenced-by-count":8,"title":["Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses"],"prefix":"10.1038","volume":"105","author":[{"given":"W M","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D W","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Gravett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A G","family":"Dalgleish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,9]]},"reference":[{"key":"BFbjc2011306_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/383787a0","volume":"383","author":"AK Abbas","year":"1996","unstructured":"Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383: 787\u2013793","journal-title":"Nature"},{"key":"BFbjc2011306_CR2","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","volume":"353","author":"AB Alexandroff","year":"1999","unstructured":"Alexandroff AB, Jackson AM, O\u2019Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689\u20131694","journal-title":"Lancet"},{"key":"BFbjc2011306_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-0-387-72005-0_13","volume":"601","author":"N Aptsiauri","year":"2007","unstructured":"Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F (2007) Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 601: 123\u2013131","journal-title":"Adv Exp Med Biol"},{"key":"BFbjc2011306_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev.immunol.15.1.563","volume":"15","author":"EA Bach","year":"1997","unstructured":"Bach EA, Aguet M, Schreiber RD (1997) The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15: 563\u2013591","journal-title":"Annu Rev Immunol"},{"key":"BFbjc2011306_CR5","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1073\/pnas.251194298","volume":"98","author":"BL Bennett","year":"2001","unstructured":"Bennett BL, Sasaki DT, Murray BW, O\u2019Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci 98: 13681\u201313686","journal-title":"Proc Natl Acad Sci"},{"key":"BFbjc2011306_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-002-0332-0","volume":"52","author":"T Cabrera","year":"2003","unstructured":"Cabrera T, L\u00f3pez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52: 1\u20139","journal-title":"Cancer Immunol Immunother"},{"key":"BFbjc2011306_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/imt.11.18","volume":"3","author":"J Copier","year":"2011","unstructured":"Copier J, Bodman-Smith M, Dalgleish A (2011) Current status and future applications of cellular therapies for cancer. Immunotherapy 3: 507\u2013516","journal-title":"Immunotherapy"},{"key":"BFbjc2011306_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0065-230X(02)84008-8","volume":"84","author":"AG Dalgleish","year":"2002","unstructured":"Dalgleish AG, O\u2019Byrne KJ (2002) Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 84: 231\u2013276","journal-title":"Adv Cancer Res"},{"key":"BFbjc2011306_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1084\/jem.20101876","volume":"208","author":"L De Monte","year":"2011","unstructured":"De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208: 469\u2013478","journal-title":"J Exp Med"},{"key":"BFbjc2011306_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-9966-30-12","volume":"30","author":"C Du","year":"2011","unstructured":"Du C, Wang Y (2011) The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res 30: 12","journal-title":"J Exp Clin Cancer Res"},{"key":"BFbjc2011306_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991\u2013998","journal-title":"Nat Immunol"},{"key":"BFbjc2011306_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0039.2007.00869.x","volume":"70","author":"JI Ellyard","year":"2007","unstructured":"Ellyard JI, Simson L, Parish CR (2007) Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 70: 1\u201311","journal-title":"Tissue Antigens"},{"key":"BFbjc2011306_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/0167-5699(93)90264-L","volume":"14","author":"F Garrido","year":"1993","unstructured":"Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14: 491\u2013499","journal-title":"Immunol Today"},{"key":"BFbjc2011306_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1054\/bjoc.1999.1034","volume":"82","author":"AG Heriot","year":"2000","unstructured":"Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82: 1009\u20131112","journal-title":"Br J Cancer"},{"key":"BFbjc2011306_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1046\/j.1464-410X.1998.00803.x","volume":"82","author":"D Hrouda","year":"1998","unstructured":"Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG (1998) Immunotherapy of advanced prostate cancer: a phase I\/II trial using Mycobacterium vaccae (SRL172). Br J Urol 82: 568\u2013573","journal-title":"Br J Urol"},{"issue":"4","key":"BFbjc2011306_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.26101","volume":"130","author":"Wai M. Liu","year":"2011","unstructured":"Liu WM, Dennis JL, Fowler DW, Dalgleish AG (2011) The gene expression profile of un-stimulated dendritic cells can be used as a predictor of function. Int J Cancer, e-pub ahead of print 31 March 2011, doi:10.1002\/ijc.26101","journal-title":"International Journal of Cancer"},{"key":"BFbjc2011306_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM, Fowler DW, Smith P, Dalgleish AG (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102: 115\u2013123","journal-title":"Br J Cancer"},{"key":"BFbjc2011306_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","volume":"21","author":"Y Luo","year":"2003","unstructured":"Luo Y, Chen X, O\u2019Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 21: 17\u201326","journal-title":"Cytokine"},{"key":"BFbjc2011306_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1023\/A:1008307821189","volume":"10","author":"A Maraveyas","year":"1999","unstructured":"Maraveyas A, Baban B, Kennard D, Rook GA, Westby M, Grange JM, Lydyard P, Stanford JL, Jones M, Selby P, Dalgleish AG (1999) Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 10: 817\u2013824","journal-title":"Ann Oncol"},{"key":"BFbjc2011306_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/00008390-200308000-00008","volume":"13","author":"S Nicholson","year":"2003","unstructured":"Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG (2003) A randomized phase II trial of SRL172 (Mycobacterium vaccae) +\/\u2212 low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res 13: 389\u2013393","journal-title":"Melanoma Res"},{"key":"BFbjc2011306_CR21","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/infdis\/167.6.1481","volume":"167","author":"IM Orme","year":"1993","unstructured":"Orme IM, Andersen P, Boom WH (1993) T cell response to Mycobacterium tuberculosis. J Infect Dis 167: 1481\u20131497","journal-title":"J Infect Dis"},{"key":"BFbjc2011306_CR22","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1158\/1078-0432.CCR-10-2114","volume":"17","author":"A Respa","year":"2011","unstructured":"Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B (2011) Association of IFN-{gamma} signal transducti. Clin Cancer Res 17: 2668\u20132678","journal-title":"Clin Cancer Res"},{"key":"BFbjc2011306_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2407-7-34","volume":"7","author":"T Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez T, M\u00e9ndez R, Del Campo A, Jim\u00e9nez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7: 34","journal-title":"BMC Cancer"},{"key":"BFbjc2011306_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature04874","volume":"441","author":"JS Sebolt-Leopold","year":"2006","unstructured":"Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of signalling molecules. Nature 441: 457\u2013462","journal-title":"Nature"},{"key":"BFbjc2011306_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0065-230X(08)00407-7","volume":"101","author":"B Seliger","year":"2008","unstructured":"Seliger B, Ruiz-Cabello F, Garrido F (2008) IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101: 249\u2013276","journal-title":"Adv Cancer Res"},{"key":"BFbjc2011306_CR26","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1073\/pnas.88.14.5989","volume":"88","author":"WJ Storkus","year":"1991","unstructured":"Storkus WJ, Salter RD, Alexander J, Ward FE, Ruiz RE, Cresswell P, Dawson JR (1991) Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2. Proc Natl Acad Sci 88: 5989\u20135992","journal-title":"Proc Natl Acad Sci"},{"key":"BFbjc2011306_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00262-006-0164-4","volume":"55","author":"TB Tomasi","year":"2006","unstructured":"Tomasi TB, Magner WJ, Khan AN (2006) Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 55: 1159\u20131184","journal-title":"Cancer Immunol Immunother"},{"key":"BFbjc2011306_CR28","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/cncr.24953","volume":"116","author":"J Yang","year":"2010","unstructured":"Yang J, Yi Q (2010) Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer 116: 1638\u20131645","journal-title":"Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2011306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011306","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2011306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:02:44Z","timestamp":1684414964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2011306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["BFbjc2011306"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2011.306","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}